Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesOrganon & Co

Organon & Co

Healthcare Drug Manufacturers - General
PortfolioPortfolio WatchlistWatchlist
Company price
13.885 USD -0.01 ( 0.04%)
Last update at 2026-11-12T15:45:00Z
VOLUME
184046
Market Cap
3555.48M
P/E
6.10

Momentum Score

…

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive; Nuvaring, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
13.87
Low
13.89
High
52 Week Price Range
10.84
Low
30.51
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
13.89
Dividend Yield
8.05%
Revenue TTM
6150.00M
Revenue Per Share
24.12
Gross Profit TTM
3889.00M
Debt / Equity
-9.99
ROE
-
Net Debt
8207.00M
ROCE
17.51%
Diluted EPS TTM
2.28

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 1122.00M 1529.00M 2680.00M 3696.00M 2729.00M
Net income 917.00M 1351.00M 2160.00M 3218.00M 2153.00M
Selling general administrative 1704.00M 1503.00M 1666.00M 1922.00M 2013.00M
Gross profit 3880.00M 3922.00M 4749.00M 5503.00M 5084.00M
Reconciled depreciation 212.00M 195.00M 157.00M 354.00M 1673.00M
Ebit 1478.00M 1619.00M 2849.00M 3847.00M 2825.00M
Ebitda 1690.00M 1814.00M 3006.00M 4180.00M 4498.00M
Depreciation and amortization 212.00M 195.00M 157.00M 333.00M 1673.00M
Operating income 1478.00M 1619.00M 2849.00M 3847.00M 2706.00M
Other operating expenses 4469.00M 4493.00M 5317.00M 3937.00M 7071.00M
Interest expense 422.00M 258.00M 169.00M 239.00M 45.00M
Tax provision 205.00M 178.00M 520.00M 337.00M 576.00M
Net interest income -422.00M -258.00M - 0.00M -
Extraordinary items 0.00M 0.00M -96.00M -88.00M -
Non recurring - 3.00M - - -
Income tax expense 205.00M 178.00M 520.00M 390.00M 576.00M
Total revenue 6174.00M 6304.00M 8096.00M 7777.00M 9777.00M
Total operating expenses 2175.00M 2111.00M 1970.00M 1663.00M 2378.00M
Cost of revenue 2294.00M 2382.00M 3347.00M 2274.00M 4693.00M
Total other income expense net -356.00M -90.00M -169.00M -151.00M 23.00M
Discontinued operations - - -96.00M -88.00M -88.00M
Net income from continuing ops 917.00M 1351.00M 2160.00M 3218.00M 2153.00M
Net income applicable to common shares 917.00M 1351.00M 2160.00M 3218.00M 2153.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 10955.00M 10681.00M 10434.00M 10548.00M 10494.00M
Intangible assets 649.00M 651.00M 503.00M 569.00M 812.00M
Other current assets 747.00M 726.00M 929.00M 1078.00M 871.00M
Total liab 11847.00M 12189.00M 11254.00M 3513.00M 4146.00M
Total stockholder equity -892.00M -1508.00M -820.00M 7035.00M 6348.00M
Deferred long term liab - 4.00M - - -
Other current liab 1353.00M 1206.00M 942.00M 1049.00M 328.00M
Common stock 3.00M 3.00M 3.00M 7949.00M 7256.00M
Capital stock 3.00M 3.00M 3.00M 0.00M -
Retained earnings -331.00M -998.00M -219.00M 0.00M -
Other liab 280.00M 283.00M 1879.00M 2034.00M 2567.00M
Good will 4603.00M 4603.00M 4603.00M 4603.00M 4603.00M
Other assets 539.00M 464.00M 347.00M 659.00M 714.00M
Cash 706.00M 737.00M 500.00M 319.00M 244.00M
Cash and equivalents 706.00M 737.00M 12.00M 319.00M 244.00M
Total current liabilities 2512.00M 2597.00M 1201.00M 1341.00M 1545.00M
Current deferred revenue 19.00M - - - -
Net debt 8207.00M 8397.00M -500.00M -215.00M -
Short term debt 8.00M 9.00M 1339.00M 34.00M 0.00M
Short long term debt 8.00M 9.00M - 34.00M -
Short long term debt total 8913.00M 9134.00M - 104.00M 34.00M
Other stockholder equity -564.00M -513.00M 216.00M 7949.00M -908.00M
Property plant equipment 1233.00M 973.00M 1089.00M 762.00M 651.00M
Total current assets 3931.00M 3760.00M 3434.00M 3955.00M 3714.00M
Net tangible assets -6144.00M -6904.00M 380.00M 1863.00M 933.00M
Net receivables 1475.00M 1382.00M 1092.00M 1487.00M 1605.00M
Long term debt 8905.00M 9125.00M 0.00M 70.00M 34.00M
Inventory 1003.00M 915.00M 913.00M 1071.00M 994.00M
Accounts payable 1132.00M 1382.00M 259.00M 258.00M 289.00M
Accumulated other comprehensive income -564.00M -513.00M -604.00M -914.00M -
Common stock total equity - 3.00M 3.00M - -
Retained earnings total equity - -998.00M - - -
Non currrent assets other 735.00M 694.00M 910.00M 741.00M -
Non current assets total 7024.00M 6921.00M 7000.00M 6593.00M -
Long term debt total 8905.00M 9125.00M 0.00M 70.00M 34.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -420.00M -481.00M -258.00M -102.00M -69.00M
Change to liabilities -237.00M 709.00M 27.00M -31.00M 20.00M
Total cashflows from investing activities -420.00M -481.00M -258.00M -102.00M -69.00M
Net borrowings -108.00M 7728.00M 1165.00M -44.00M 59.00M
Total cash from financing activities -433.00M -1333.00M -2175.00M -2621.00M -4164.00M
Change to operating activities 121.00M 573.00M -236.00M -214.00M -322.00M
Net income 917.00M 1351.00M 2160.00M 3306.00M 2153.00M
Change in cash -31.00M 667.00M -249.00M 75.00M -527.00M
Begin period cash flow 737.00M 70.00M 319.00M 244.00M 771.00M
End period cash flow 706.00M 737.00M 70.00M 319.00M 244.00M
Total cash from operating activities 858.00M 2458.00M 2187.00M 2767.00M 3687.00M
Depreciation 212.00M 195.00M 157.00M 333.00M 1673.00M
Other cashflows from investing activities -117.00M -289.00M 20.00M 7.00M 32.00M
Dividends paid 290.00M 145.00M 145.00M 145.00M 145.00M
Change to inventory -220.00M -138.00M -29.00M -91.00M 44.00M
Change to account receivables -123.00M -277.00M 159.00M 200.00M 250.00M
Other cashflows from financing activities -35.00M 436.00M -2096.00M -2621.00M -4164.00M
Change to netincome 181.00M 210.00M 67.00M 107.00M 35.00M
Capital expenditures 427.00M 488.00M 278.00M 92.00M 101.00M
Change receivables - -277.00M - - -
Cash flows other operating - 1759.00M - - -
Cash and cash equivalents changes - 702.00M - - -
Change in working capital -452.00M 702.00M -197.00M -672.00M -174.00M
Stock based compensation 75.00M 59.00M 54.00M 41.00M 56.00M
Other non cash items 124.00M 439.00M 7.00M -253.00M -58.00M
Free cash flow 431.00M 1970.00M 1909.00M 2675.00M 3586.00M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - General

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
OGN
Organon & Co		 -0.01
0.04%		 13.88 6.10 5.03 0.55 1.84 1.89 8.14
LLY
Eli Lilly and Company		 5.20
0.36%		 1442.49 38.16 24.15 12.72 29.95 13.31 25.43
JNJ
Johnson & Johnson		 3.95
1.41%		 284.36 30.96 20.79 6.58 7.55 6.84 19.73
ABBV
AbbVie Inc		 1.13
0.38%		 296.11 74.10 16.21 7.22 50.46 8.18 27.04
RHHVF
Roche Holding AG Participation		 1.60
0.33%		 486.40 24.16 16.53 5.71 8.88 4.94 14.76

Profile*

Organon & Co

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive; Nuvaring, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.

30 Hudson Street, Jersey City, NJ, United States, 07302

551 430 6000

https://www.organon.com

10000

Name Title Year Born
Mr. Kevin Ali CEO & Director 1960
Mr. Matthew M. Walsh Exec. VP & CFO 1967
Ms. Susanne Gabriele Fiedler Exec. VP & Chief Commercial Officer 1968
Dr. Sandra Milligan J.D., M.D. Exec. VP and Head of R&D 1964
Ms. Rachel A. Stahler Exec. VP & Chief Information Officer 1976
Ms. Jennifer Halchak VP of Investor Relations NA
Mr. Kirke Weaver Gen. Counsel & Corp. Sec. NA
Mr. Aaron Falcione Exec. VP & Chief HR Officer 1971
Mr. Joseph T. Morrissey Jr. Exec. VP and Head of Manufacturing & Supply 1965
Mr. Vittorio Nisita Exec. VP & Head of Global Bus. Services 1968

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…